Variation in the stress response between high- and low-neuroticism female undergraduates across the menstrual cycle

This study was undertaken to elucidate possible relationships between menstrual cycle stage, neuroticism and behavioral and physiological responses to a cognitive challenge. The study investigated the differences between high neuroticism and low neuroticism groups across the menstrual cycle (luteal, menstrual and ovulatory stages). The Stroop color-naming task was used as a stressor. During the task, the galvanic skin response (GSR), heart rate (HR) and HR variability (HRV) were simultaneously recorded by a polygraph. The results showed a significant difference in reaction times (RT) on the Stroop task between the high-and low-neuroticism groups during menstruation. However, there were no significant RT differences between groups during the luteal or ovulatory cycle stages. The GSR of the high-neuroticism group during menstruation was significantly lower than it was in the luteal and ovulatory stages. Moreover, during menstruation, the cardiovascular responses (high-frequency HRV (HF) and low-frequency HRV (LF)) and accuracy on the Stroop task were positively correlated, while the correlations between HF, LF and the RT were negative. The results demonstrate that during menstruation, there were consistent variations in female behavior and physiology when facing a cognitive stressor. Specifically, the high-neuroticism group was more sensitive to the stressor than the low neuroticism group, with decreased reaction time on the Stroop task, and increased GSR and HRV

Oxytocin Attenuates Amygdala Reactivity to Fear in Generalized Social Anxiety Disorder

Patients with generalized social anxiety disorder (GSAD) exhibit heightened activation of the amygdala in response to social cues conveying threat (eg, fearful/angry faces). The neuropeptide oxytocin (OXT) decreases anxiety and stress, facilitates social encounters, and attenuates amygdala reactivity to threatening faces in healthy subjects. The goal of this study was to examine the effects of OXT on fear-related amygdala reactivity in GSAD and matched healthy control (CON) subjects. In a functional magnetic resonance imaging study utilizing a double-blind placebo-controlled within-subjects design, we measured amygdala activation to an emotional face matching task of fearful, angry, and happy faces following acute intranasal administration of OXT (24 IU or 40.32 μg) and placebo in 18 GSAD and 18 CON subjects. Both the CON and GSAD groups activated bilateral amygdala to all emotional faces during placebo, with the GSAD group exhibiting hyperactivity specifically to fearful faces in bilateral amygdala compared with the CON group. OXT had no effect on amygdala activity to emotional faces in the CON group, but attenuated the heightened amygdala reactivity to fearful faces in the GSAD group, such that the hyperactivity observed during the placebo session was no longer evident following OXT (ie, normalization). These findings suggest that OXT has a specific effect on fear-related amygdala activity, particularly when the amygdala is hyperactive, such as in GSAD, thereby providing a brain-based mechanism of the impact of OXT in modulating the exaggerated processing of social signals of threat in patients with pathological anxiety